WuXi AppTec sues Pentagon over Chinese military list designation

WuXi AppTec moved quickly to challenge the Pentagon’s latest military-company designation, filing a complaint in federal court in Washington that seeks to wipe the label from the record. The Chinese drugmaker says the designation threatens far more than its reputation: it reaches into contracts, investor confidence and the ability of globally integrated biotech firms to do business across borders.

The company filed its case in the U.S. District Court for the District of Columbia on June 11, just a day after the Defense Department published its updated Section 1260H list. That notice, issued under the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021, said the listed entities satisfy the requirements to be designated as Chinese military companies. WuXi AppTec has asked the court to declare the designation null and void, saying the government’s characterization is erroneous and unsupported by the facts or legal criteria.

The dispute lands at the center of a broader national-security fight over life sciences. A company placed on the 1260H list can face procurement and compliance fallout, including potential consequences under the BIOSECURE Act, which would restrict certain federal purchases and grants involving equipment or services tied to the firms on that list. For drugmakers that rely on outsourced research, testing and manufacturing, that kind of designation can change how quickly business is done, what counterparties are willing to sign, and how much risk investors think they are underwriting.

WuXi AppTec is not a small or obscure player. It is a major global life-sciences services company with customers across the pharmaceutical industry, and its U.S. footprint gives the dispute added weight. Its subsidiary, WuXi STA, broke ground on a manufacturing campus in Middletown, Delaware, in 2022, underscoring how deeply the company’s operations are tied into the U.S. market even as Washington treats the firm through a national-security lens.

The June 2026 update expanded the Pentagon’s roster to 188 Chinese entities, adding other well-known names including Alibaba and Baidu. That breadth matters because it shows the government is not only targeting defense contractors or obscure suppliers, but also commercial giants with wide civilian reach. For Washington, the list is a policy tool meant to manage security risk. For WuXi AppTec and other affected firms, it is a blunt instrument with immediate commercial consequences.

The case now puts a familiar question before the court: when the government attaches a military label to a private company, how much evidence is enough to justify the damage that follows?